Aptevo Therapeutics Reports Third Quarter 2017 Financial Results
November 09, 2017 16:30 ET
|
Aptevo Therapeutics Inc.
Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in Cash at the End of the Third Quarter Expanded Novel Bispecific Antibody Portfolio Through...
Aptevo Therapeutics Presents New Preclinical Data on APVO436 – a Next Generation ADAPTIR™ Bispecific Antibody Candidate
October 30, 2017 09:02 ET
|
Aptevo Therapeutics Inc.
New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors SEATTLE, Oct. 30, 2017 (GLOBE NEWSWIRE)...
Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 – a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics
October 24, 2017 09:00 ET
|
Aptevo Therapeutics Inc.; Alligator Bioscience
ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications LUND, Sweden and SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Alligator Bioscience...
Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting
October 16, 2017 09:02 ET
|
Aptevo Therapeutics
New Autoimmune Candidate APVO210 Demonstrates Targeted Cytokine Delivery for Application in Various Autoimmune and Inflammatory Diseases SEATTLE, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aptevo...
Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR™ Bispecific Platform at the World Bispecific Summit
October 02, 2017 09:00 ET
|
Aptevo Therapeutics
SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced...
Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial
September 28, 2017 16:45 ET
|
Aptevo Therapeutics
SEATTLE, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced...
Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million
September 28, 2017 16:35 ET
|
Aptevo Therapeutics
Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset Strengthens Cash Position to Advance R&D and Commercial Strategy SEATTLE, Sept. 28, 2017 (GLOBE...
Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products
August 31, 2017 17:16 ET
|
Aptevo Therapeutics
Provides Significant Non-Dilutive Funding to Execute R&D Strategy Sharpens Focus on Proprietary ADAPTIR™ Protein Therapeutic Platform Retains IXINITY® Commercial Asset SEATTLE, Aug. 31, 2017 ...
Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414
August 31, 2017 17:15 ET
|
Aptevo Therapeutics
Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414 Preliminary Phase I Data Show Markedly Lower Anti-Drug Antibody Titers Demonstrating Effectiveness...
Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527
August 17, 2017 07:00 ET
|
Aptevo Therapeutics
Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications SEATTLE and LUND, Sweden, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc....